Preventing tuberculosis in children with and without HIV
TUBERCULOSIS PREVENTION IN CHILDREN TWO TO LESS THAN 13 YEARS OF AGE WITH AND WITHOUT HIV
This study is looking at how well a daily combination of two medicines, Rifapentine and Isoniazid, can help prevent tuberculosis in children aged 2 to under 13, especially those living with HIV, and it will check how safe and easy the treatment is for them.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Westat, INC. NIH-funded |
| Lab location | 1 site (Rockville, United States) |
| Project ID | NIH-10872953 on NIH RePORTER |
What this research studies
This research investigates the effectiveness of a combination of daily Rifapentine and Isoniazid for preventing tuberculosis in children aged two to less than 13 years, including those living with HIV. The study aims to determine the appropriate dosage, safety, and tolerability of this treatment regimen. By participating, children will be monitored closely to assess how well the medication works and any side effects that may occur. The research is part of a larger initiative to improve health outcomes for vulnerable populations, particularly in the context of HIV.
Who could benefit from this research
Good fit: Ideal candidates for this research are children aged two to less than 13 years, both with and without HIV.
Not a fit: Patients outside the specified age range or those without a risk of tuberculosis may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could significantly reduce the incidence of tuberculosis in children, especially those at higher risk due to HIV.
How similar studies have performed: Previous research has shown promise in using similar drug combinations for tuberculosis prevention, indicating potential for success in this approach.
Where this research is happening
Rockville, United States
- Westat, INC. — Rockville, United States (Active)
Researchers
- Principal investigator: Driver, Barbara — Westat, INC.
- Study coordinator: Driver, Barbara
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.